What Is Cinnamycin? Definition and What Research Reports

Definition

Cinnamycin (also written Ro 09-0198) is a 19-amino-acid, heavily cross-linked peptide produced by soil actinomycete bacteria of the genus Streptomyces. It belongs to the lantibiotic family — ribosomally synthesised peptides that are extensively modified after translation to contain thioether-bridged amino acids such as lanthionine and methyllanthionine. Cinnamycin is the type member of a small group of "type B" lantibiotics that also includes duramycin. Its defining laboratory property is that it recognises and binds a specific membrane phospholipid, phosphatidylethanolamine (PE), rather than acting on a protein target. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, treatment or medical decisions.

What Class of Molecule Is It, and Where Does It Come From?

Cinnamycin is a ribosomally synthesised and post-translationally modified peptide (RiPP). That means the bacterium first makes a normal gene-encoded precursor peptide and then enzymes rebuild parts of it chemically. Researchers who cloned and engineered the cinnamycin biosynthetic gene cluster from Streptomyces cinnamoneus cinnamoneus DSM 40005 reported the gene set responsible for producing the peptide and showed that it could be expressed and manipulated in a heterologous host. A later chemical study of the pathway described nine distinct post-translational modifications occurring during cinnamycin biosynthesis, which is unusually high for a peptide of this size and accounts for its rigid, cage-like three-dimensional shape.

The genus is not the only source. A genome-mining study isolated and determined the structure of a related lantibiotic, cinnamycin B, from Actinomadura atramentaria, showing that cinnamycin-type chemistry is distributed across more than one actinomycete lineage. Producer organisms must also protect themselves from their own product; work in Streptomyces cinnamoneus DSM 40646 described a self-immunity mechanism that controls when cinnamycin biosynthesis begins.

Quick reference

How the Term Is Used in Peptide Research

In the peptide and membrane-biophysics literature, "cinnamycin" is used in three overlapping ways.

• As a lipid-binding probe. Because the peptide recognises PE, investigators have used it — and its close relative duramycin — to detect where PE sits in a membrane. A review of this approach described the use of duramycin/cinnamycin together with aegerolysin proteins to probe phosphoethanolamine-containing lipids in membranes.
• As a model system for peptide–lipid recognition. The cinnamycin–PE interaction is one of the better-characterised examples of a small peptide binding a single lipid headgroup, and it appears repeatedly in biophysics papers as a test case for binding models and simulation methods.
• As a case study in lanthipeptide biosynthesis. Because the pathway installs an unusually large number of modifications, cinnamycin is cited in RiPP enzymology as an example of complex post-translational chemistry, as in the study that catalogued nine post-translational modifications in its biosynthesis.

What the Published Literature Reports

Binding to phosphatidylethanolamine

The most consistently reported property of cinnamycin is selective lipid binding. A thermodynamic analysis of the interaction reported specific binding of Ro 09-0198 to phosphatidylethanolamine, and a follow-up study compared that binding between micellar and membrane environments, indicating that the surrounding lipid assembly influences how the peptide engages its target. Using surface plasmon resonance, researchers carried out kinetic and thermodynamic measurements of cinnamycin adsorption onto PE-included membranes, providing rate and affinity descriptions of the same interaction in a label-free format.

Membrane geometry also matters. One study examined the curvature effect of a PE-containing membrane on the behaviour of cinnamycin on that membrane, and a molecular-simulation paper described the structure and dynamics of cinnamycin–lipid complexes and proposed mechanisms underlying selectivity for phosphatidylethanolamine lipids. Together these reports frame cinnamycin's selectivity as a product of both headgroup chemistry and the physical state of the bilayer.

Effects on membranes and cells

Binding is not passive. In one mechanistic study, researchers reported that cinnamycin (Ro 09-0198) promoted cell binding and toxicity by inducing transbilayer lipid movement — that is, the peptide appeared to scramble lipids between the two leaflets of the membrane, and the study linked this movement to its cytotoxic activity. This is the principal published account of how membrane binding translates into a cellular effect, and it is the reason cinnamycin is generally treated as a membrane-active laboratory reagent rather than a benign stain.

Engineered and immobilised formats

Researchers have also attached cinnamycin to surfaces and nanomaterials to exploit its lipid selectivity. One report examined the interactions of cinnamycin-immobilised gold nanorods with biomimetic membranes, extending the peptide's use from solution assays into nanoparticle-based membrane sensing. On the production side, the cloning work from DSM 40005 reported engineering of the biosynthetic gene cluster, which in principle allows analogues to be generated genetically rather than by total synthesis.

Cinnamycin Safety: What Studies Report

The verified literature summarised here is laboratory and microbiological in nature; it does not include human clinical trials, dosing studies, or safety monitoring in people, and no dose figures for humans appear in these papers. The clearest cell-level finding is the mechanistic report in which researchers described cinnamycin-induced transbilayer lipid movement as the basis of its cell binding and toxicity. Because the peptide's target, phosphatidylethanolamine, is a common lipid in many biological membranes — and the reason it works as a broad membrane probe, as discussed in the review of duramycin/cinnamycin and aegerolysin probes — its activity is not confined to a single organism or cell type in vitro. Nothing in this literature establishes safety or efficacy in humans, and cinnamycin is not an approved medicine.

Related Terms

• Lantibiotic / lanthipeptide — the peptide class defined by thioether (lanthionine) bridges, to which cinnamycin belongs.
• Duramycin — a closely related PE-binding lantibiotic frequently studied alongside cinnamycin, including in the review of PE-lipid probes.
• Cinnamycin B — a structural variant isolated and structurally determined from Actinomadura atramentaria via genome mining.
• Phosphatidylethanolamine (PE) — the membrane phospholipid cinnamycin recognises.
• RiPP — ribosomally synthesised and post-translationally modified peptide; cinnamycin's nine reported post-translational modifications make it a textbook example.

Summary of the Evidence Base

Across the studies cited here, cinnamycin appears mainly as a biophysical tool and a biosynthetic curiosity rather than a therapeutic candidate. Genetics and enzymology papers explain how the producer organism builds and tolerates it, binding studies quantify its preference for phosphatidylethanolamine in micelles and bilayers, simulation and curvature work explain why that preference exists, and one mechanistic study connects binding to lipid scrambling and cytotoxicity. Readers looking for human outcome data will not find it in this set of papers.

References

• Cinnamycin (Ro 09-0198) promotes cell binding and toxicity by inducing transbilayer lipid movement (The Journal of Biological Chemistry, 2003)
• Curvature Effect of a Phosphatidylethanolamine-Included Membrane on the Behavior of Cinnamycin on the Membrane (The Journal of Physical Chemistry B, 2020)
• Cloning and engineering of the cinnamycin biosynthetic gene cluster from Streptomyces cinnamoneus cinnamoneus DSM 40005 (PNAS, 2003)
• Probing phosphoethanolamine-containing lipids in membranes with duramycin/cinnamycin and aegerolysin proteins (Biochimie, 2016)
• Kinetic and thermodynamic studies of cinnamycin specific-adsorption on PE-Included-Membranes using surface plasmon resonance (Journal of Biotechnology, 2020)
• Specific binding of Ro 09-0198 (cinnamycin) to phosphatidylethanolamine: a thermodynamic analysis (Biochemistry, 2002)
• A novel mechanism of immunity controls the onset of cinnamycin biosynthesis in Streptomyces cinnamoneus DSM 40646 (Journal of Industrial Microbiology & Biotechnology, 2017)
• Structure and Dynamics of Cinnamycin-Lipid Complexes: Mechanisms of Selectivity for Phosphatidylethanolamine Lipids (ACS Omega, 2019)
• Isolation and structure determination of a new lantibiotic cinnamycin B from Actinomadura atramentaria based on genome mining (Journal of Industrial Microbiology & Biotechnology, 2016)
• Specific binding of cinnamycin (Ro 09-0198) to phosphatidylethanolamine. Comparison between micellar and membrane environments (Biochemistry, 2003)
• Nine post-translational modifications during the biosynthesis of cinnamycin (Journal of the American Chemical Society, 2011)
• Interactions of Cinnamycin-Immobilized Gold Nanorods with Biomimetic Membranes (The Journal of Membrane Biology, 2020)